COMET CLINICAL TRIALS CONSORTIUM. June 2016 Newsletter Volume 4 Issue 6. PG 3 Member and Trials Snapshot. Letter from Dr. Brezden-Masley, Founder
|
|
- Damian O’Brien’
- 6 years ago
- Views:
Transcription
1 COMET CLINICAL TRIALS CONSORTIUM June 2016 Newsletter Volume 4 Issue 6 PG 1 Trials of the Month PG 3 Member and Trials Snapshot PG 4 Website Functions Trials of the Month Type Trial Site Breast IMpassion 130 Lakeridge Letter from Dr. Brezden-Masley, Founder This has been a great year for COMET and we hope that you are enjoying the website and all the services it offers. Since its launch in 2011, COMET has grown in popularity and is a central hub for over 130 clinical trials in Ontario! CNS CNS MRI pseudopro -gression We are always making improvements to make COMET better for our users! If you have any suggestions, please do not hesitate to contact us at comettrials@smh.ca and we are more than happy to assist. GU BRIGHTER Mount Sinai, St.Micheal s Haem HBV St. Michael s GYNE IND.221 Lung Mel GI IMpower 131 Melanoma Neoadjuva -nt NCIC CO. 21 Royal Victoria Odette Kingston, Mount Sinai, Odette, Southlake, Trillium Sincerely, Dr. Christine Brezden-Masley Founder, COMET Clinical Trials Consortium Letter from Suruthi Senthilvel, Project Manager April showers bring May flowers! And with that, we can say spring is here! We hope that CCTC has been helpful in transitioning the gap between patient referrals and newly emerging clinical trials. We are open to feedback from all our members to better COMET s features for all out members! Our main goals are to make the CCTC more user-friendly by incorporating your continued input to better it! For any inquiries, please contact me at comettrials@smh.ca! Many thanks, Suruthi Senthilvel Project Manager, CCTC June 2016 Newsletter 1
2 TRIALS OF THE MONTH Type Acronym Study Title Description Site(s) Breast IMpassion130 A Phase III, Multicenter, Randomized Placebo-Controlled Study of Atezolizumab (MPDL3280A) (Anti-PD-L1 Antibody) in Combination With Nab Paclitaxel Compared With Placebo With Nab Paclitaxel for Patients With Previously Untreated Metastatic Triple Negative Breast Cancer - Any HER2 - Metastatic (1st, 2nd, 3rd or 4th Lakeridge Health Corporation CNS CNS MRI pseudoprogression Differentiation of Pseudoprogression and True Progression Through High Field Susceptibility Weighted Imaging and R2* - Imaging Study Sciences GU BRIGHTER A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer (BRIGHTER) Haem HBV A Multi-centre Phase III Study to Evaluate Preemptive Tenofovir for Prevention of Hepatitis B Virus Reactivation in HBsAg Negative/Anti-HBc Positive Individuals Undergoing Rituximab-based Chemotherapy for Non-Hodgkin s Lymphoma GYNE IND.221 Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies Lung IMpower 131 A Phase III, Open-label, Multicenter, Randomzed Study Evaluating the Efficacy and Safety of MPDL3208A (Anti-PDL-1 Antibody) in Combination With Carboplatin + Paclitaxel or MPDL3208A in Combination With Carboplatin + Nab-paclitaxel Versus Carboplatin + Nab-paclitaxel in Chemotherapy-naive Patients With Stage IV Squamous Non-small Cell Lung Cancer - Gastric/Stomach Cancer - Metastatic (1st, 2nd, 3rd or 4th - Non-Hodgkin's Lymphoma - Prevention - Ovarian Cancer - Metastatic - Non-Small Cell Lung Cancer - Metastatic (1st Mount Sinai, St. Michael s St. Michael s Sciences Royal Victoria Regional Health Mel Melanoma Neoadjuvant Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases - Tumour Stage III Odette Cancer GI NCIC CO.21 A Phase III Study of the Impact of a Physical Activity Program on Disease-Free Survival in Patients With High Risk Stage II or Stage III Colon Cancer: A Randomized Controlled Trial (CHALLENGE) - Colon Cancer - Tumour Stage II/III - Prevention Study Kingston General, Sciences, Mount Sinai, Odette, June 2016 Newsletter Southlake, 2 Trillium
3 Trials Snapshot Trial Type Breast CNS GI GU GYNE H&N HEME Lung Melanoma NETs Total Trials Imaging Study Prevention Radiation Supportive Care 1 1 Surgical Therapy Systemic Therapy Therapeutic Total Trials Registered Members and Trials Per Institution Institution Members Trials Cambridge Memorial 3 2 Grand River 8 1 Hamilton Health Sciences 6 - Humber River Regional 6 - Kingston General 3 8 Juravinski Cancer 6 1 Lakeridge Health CorporaDon Science 7 63 Mackenzie Health 4 - Markham Stouffville 1 - Institution Members Trials Southlake Regional Health 12 6 St. Joseph s Healthcare (Hamilton) 4 - St. Joseph s Health (Toronto) 6 1 St. Michael s 11 3 Thunder Bay Regional 2 - Toronto General 3 1 Toronto East General 8 1 Trillium Health Partners 16 1 William Osler Health Systems 2 - Windsor Regional 1 - Mount Sinai 2 4 North York General 9 1 OdeMe Cancer / Sunnybrook Ontario InsDtute for Cancer Research 2 - OMawa 1 - Princess Margaret Cancer 19 3 Rouge Valley Health System 2 - Royal Victoria Regional Health Scarborough General 1 - COMET Summary 200+ Members 28 Institutions 130 accruing trials Newest Initiative One of the main features of COMET is its referrals process and we want to hear from you! All your feedback will be integrated to better our referrals process for physicians across the province! Send us a at comettrials@smh.ca. June 2016 Newsletter 3
4 Website Functions: Part 1 Search Clinical Trials Once logged in, click Search Trials on the top bar. Then use the drop down menus or Search by Keyword for clinical trials matching your patient;s specifications. erefer Patients If you see a trial that your patient might be eligible for, click PI &CRC on the trial s page to open the erefferal window. Simply state your interest in referring a patient and click send. Post Clinical Trials When on your Account page, click Post Trial tab to post a new clinical trial at your institution,. The statue of your posted trials will appear on the right. Edit posted trials by clicking their titles. Trial will be reviewed and posted by the end of the day. June 2016 Newsletter 4
5 Website Functions: Part 2 Add Your Institution See a trial that is already posted but you are not listed as an available institution? Choose the PI and CRC of that trial at the bottom of the trial page and click the Add my Institution to This Trial button. Membership Directory Thinking about collaborating with other institutions? Go to the Membership Directory tab to view all the CCTC members. Click their addressed to open a window to them. Acknowledgements The CCTC has been funded by unrestricted educational grants form the following supporters: Contact Us If you have any questions please do not hesitate to contact us: 30 Bond Street Toronto, ON Canada M5B 1W8 E: comettrials@smh.ca T: (416) June 2016 Newsletter 5
Ontario s Initiatives in Surgical Quality- The Successes & Where We are Going
Ontario s Initiatives in Surgical Quality- The Successes & Where We are Going Robin S. McLeod Professor of Surgery and Health Policy, Management and Evaluation University of Toronto Lead, Quality Improvement
More informationQuarter Performance Report
Canadian Cancer Clinical Trials Network Quarter Performance Report Quarter, FY 08/9 (Year 5): July Sept. 30, 08 Report Created: January 4, 09 Table of Contents Section A: Patient access and recruitment
More informationQuarter Performance Report
Canadian Cancer Clinical Trials Network Quarter Performance Report Quarter 07/8: April June 30, 07 Report Created: Sept 8, 07 Table of Contents Section A: Progress at Adult Network Sites... Section B:
More informationSpecialized Geriatric Services
Specialized Geriatric Services Toronto and Surrounding Area Frail seniors with complex health problems have unique needs and present specific challenges for accurate assessment, diagnosis and treatment.
More informationProvincial Sarcoma Services Plan VERSION 2.0 DECEMBER 2015
Provincial Sarcoma Services Plan 1 VERSION 2.0 DECEMBER 2015 PROVINCIAL SARCOMA SERVICES PLAN Contents What is the Provincial Sarcoma Services Plan? 3 The Rationale for Organizing Sarcoma Services The
More informationProvincial Interprofessional Stroke Core Competency Framework with a TR Focus
Provincial Interprofessional Stroke Core Competency Framework with a TR Focus Thursday June 1st, 2017 3:00 4:00 p.m. T14 Provincial TR Stroke Core Competencies Presenters Keli Cristofaro R/TRO Stroke Community
More informationHIGHLIGHTS REPORT 2016/17. (April 1, 2016 March 31, 2017)
HIGHLIGHTS REPORT 2016/17 (April 1, 2016 March 31, 2017) Transplant Highlights Transplantation Total Transplants 1,256 As of March 31, 2017, there were 1,556 Ontarians waiting for a lifesaving transplant
More informationTreatment Guidelines & Clinical Outcomes User Guide
Treatment Guidelines & Clinical Outcomes User Guide For questions about McKesson Clinical Tools, email us at msh.providers@mckesson.com. Treatment Guidelines and Clinical Outcomes User Guide Table of Contents
More informationCLINICAL TRIALS ACC. Jul 2016
CLINICAL TRIALS ACC Jul 2016 Glioblastoma BRAIN A071102 A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
More informationStage Data Capture in Ontario
Stage Data Capture in Ontario February 23, 2010 Agenda Refresher: Ontario s Stage Capture Project Collaborative Staging and Population Stage Reporting in Ontario Use of Stage Data in System Performance
More informationBuilding a Culture of Donation. 2017/18 Highlights Report
Building a Culture of Donation 2017/18 Highlights Report 2017/18 TRANSPLANT HIGHLIGHTS Transplants from living donors 270 Transplants from deceased donors 993 Total transplants in Ontario (Living and deceased
More informationStructured Pathology Reporting of Cancer Newsletter
Structured Pathology Reporting of Cancer Newsletter December 2012. Issue 12. Index : (click on a title below to go directly to that story) Welcome to the last edition of the Structured Pathology Reporting
More informationPartnering to Save Lives
Partnering to Save Lives Trillium Gift of Life Network Annual Report 2013/14 Mission Saving and enhancing more lives through the gift of organ and tissue donation and transplantation in Ontario. Vision
More informationNow Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
A service of the U.S. National Institutes of Health Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting Trial record 1 of 1 for: Keynote 355 Previous Study Return to List
More informationThe Clinical Research E-News
Volume 3: ISSUE 3: February 16, 2011 The Clinical Research E-News Now Open: RTOG 0631, Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis RTOG 1010, A Phase III Trial Evaluating
More informationThe Clinical Research E-News
Volume 3: ISSUE 4: March 2, 2011 The Clinical Research E-News Now Open: E1608, A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients with Advanced Melanoma E2208, Randomized Phase II Study of
More informationmehealth for ADHD Parent Manual
mehealth for ADHD adhd.mehealthom.com mehealth for ADHD Parent Manual al Version 1.0 Revised 11/05/2008 mehealth for ADHD is a team-oriented approach where parents and teachers assist healthcare providers
More informationCOSD & Source of Referral
COSD & Source of Referral A Brief guide October 2014 Michael Sharpe Data Improvement Manager National Cancer Registration Service What is COSD? Cancer and Outcomes Services Dataset Clinical dataset for
More informationRGP Operational Plan Approved by TC LHIN Updated Dec 22, 2017
RGP Operational Plan 2017-2018 Approved by TC LHIN Updated Dec 22, 2017 1 Table of Contents Introduction... 1 Vision for the Future of Services for Frail Older Adults... 1 Transition Activities High Level
More informationCare Pathways User Guide
Care Pathways User Guide For questions about McKesson Clinical Tools, email us at msh.providers@mckesson.com. Care Pathways User Guide Table of Contents Introduction to Care Pathways... 3 Launching Care
More informationThe Clinical Research E-News
Volume 3: ISSUE 5: March 23, 2011 The Clinical Research E-News Now Open: CALGB 90802, Randomized Phase III trial comparing everolimus plus placebo versus everolimus plus bevacizumab for advanced renal
More informationPROVINCIAL LEAD AND LHIN LEADER BIOS
PROVINCIAL LEAD AND LHIN LEADER BIOS May 4, 2006 Dr. Bernard Lawless, Provincial Lead Dr. Bernard Lawless completed a residency in general surgery at the University of Western Ontario (UWO) and then did
More informationOpen Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD
Open Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD Hanahan and Weinberg, 2000 Acquired Capabilities of Cancer Clinical Trials When should I consider a clinical trial? How do I find the right
More informationWASHINGTON. Spokane Cheney. Olympia. Tri-Cities. Walla Walla. Portland North Central Oregon City OREGON. Mt. Vernon. Port Angeles
2 3 Mt. Vernon Port Angeles Bremerton Tacoma 5 5 Olympia Everett Edmonds Seattle 90 WASHINGTON 90 Spokane Cheney Pullman Longview 82 Tri-Cities Portland North Central Oregon City 5 84 OREGON Walla Walla
More informationThe Clinical Research E-News
Volume 3: ISSUE 9: May 18, 2011 The Clinical Research E-News Jefferson Kimmel Cancer Network: For urgent clinical trial questions or assistance please page: 877-656-9004 Now Open: RTOG 0837, A Randomized,
More informationCancer Decision Support Tool Walk through user guide
These screenshots show exactly how a GP should use the CDS tool, covering the three ways in which it works, and how to log in to the software. Logging into the software It s really easy to log into the
More informationSUPPLEMENTARY INFORMATION
SUPPLEMENTARY NFORMATON n format provided by Melero et al. (AUGUST 2015) Supplementary nformation S3 Combinations including two or more immunotherapy agents based on PD-1/PD-L1 blockade. (Source: https://clinicaltrials.gov/
More informationThe Clinical Research E-News
The Clinical Research E-News Volume 6: ISSUE 5: June 12, 2014 Jefferson Kimmel Cancer Center Network: For urgent clinical trial questions or assistance please page: 877-656-9004 New Featured Trials Actively
More informationManagement of Inflammatory Breast Cancer: Collaboration is the path forward
Management of Inflammatory Breast Cancer: Collaboration is the path forward Massimo Cristofanilli, M.D., F.A.C.P. Professor of Medicine Associate Director of Translational Research and Precision Medicine
More informationOpen clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD
CLINICAL TRIALS Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS
More informationThe Clinical Research E-News
The Clinical Research E-News Volume 6: ISSUE 5: May 14, 2014 Jefferson Kimmel Cancer Center Network: For urgent clinical trial questions or assistance please page: 877-656-9004 New Featured Trials Actively
More informationThe Clinical Research E-News
Volume 3: ISSUE 11: June 15, 2011 The Clinical Research E-News Reminder: CRA Quarterly Meeting, Philadelphia, PA: 10-11am on Wednesday June 22nd- Virtual Meeting: dial information attached in a separate
More informationThe Clinical Research E-News
Volume 3: ISSUE 8: May 5, 2011 The Clinical Research E-News Jefferson Kimmel Cancer Network: For urgent clinical trial questions or assistance please page: 877-656-9004 Now Open: E2906, Phase III randomized
More informationStructured Pathology Reporting of Cancer Newsletter
Structured Pathology Reporting of Cancer Newsletter Welcome to the September 2010 edition of the Structured Pathology Reporting of Cancer newsletter. This newsletter is intended to provide information
More informationCheckpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
More informationCancer in Halton. Halton Region Cancer Incidence and Mortality Report
Cancer in Halton Halton Region Cancer Incidence and Mortality Report 2008 2012 The Regional Municipality of Halton March 2017 Reference: Halton Region Health Department, Cancer in Halton: Halton Region
More informationNCIC CTG Overview and Opportunities. Ralph Meyer Director, NCIC CTG
NCIC CTG Overview and Opportunities Ralph Meyer Director, NCIC CTG NCIC Clinical Trials Group A research organization A cooperative clinical trials group Previously funded by NCIC Now funded by CCSRI National
More informationCEASE: A novel electronic patient directed knowledge translation tool to improve smoking cessation in cancer patients
CEASE: A novel electronic patient directed knowledge translation tool to improve smoking cessation in cancer patients Meredith Giuliani, Geoffrey Liu, Mihaela Dirlea, Victoria Milne, Peter Selby, David
More informationOpen clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1
More informationShepherdbase (Church Membership Database) Screen Shots
Shepherdbase (Church Membership Database) Screen Shots Shepherdbase Screen Shots are available for FreeChurchForms.com visitors to view. Shepherdbase was created to help small to medium-sized churches
More informationDrug Prior Authorization Form Opdivo (nivolumab)
This document contains both information and form fields. To read information, use the Down Arrow from a form field. Drug Prior Authorization Form The purpose of this form is to obtain information required
More informationEarly Integration of Palliative Care
Early Integration of Palliative Care Dr. Camilla Zimmermann Head, Palliative Care Program University Health Network Toronto November 1, 2014 www.fpon.ca Early Integration of Palliative Care: Evidence and
More informationThe Clinical Research E-News
Volume 2: ISSUE 6: March 24, 2010 The Clinical Research E-News SPECIAL ALERT: The annual JOG investigator Meeting will be held at 5pm on May 10, 2010 at the Loews Hotel. Now Open: AZ1071, A Phase II Study
More informationOpen and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona
Open and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona Solid Tumor: USON 15180 / A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab
More informationThe Clinical Research E-News
Volume 3: ISSUE 2: January 26, 2011 The Clinical Research E-News Now Open: E2208, Randomized Phase II Study of Paclitaxel With or Without the Anti- IGF-IR mab Cixutumumab (IMC-A12) as Second Line Treatment
More informationThe Clinical Research E-News
The Clinical Research E-News Volume 2: ISSUE 23: December 16, 2010 Coming soon: E1608, A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients with Advanced Melanoma E2208, Randomized Phase II Study
More informationCancer Awareness Talk ICPAK 2014
Cancer Awareness Talk ICPAK 2014 F. Chite Asirwa, MB ChB. MD. MSc. Internist. Medical Oncologist & Hematologist Asst. Professor of Medicine Division of Hematology/Oncology Indiana University Email: fasirwa@iu.edu
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 9 Last Review Date: November 30, 2018 Keytruda Description Keytruda
More informationCancer Registry Report. Cancer Focus: Melanoma
Cancer Registry Report Cancer Focus: Melanoma In 2005, nearly 60,000 patients were diagnosed with melanoma, resulting in about 7800 deaths Fortunately, melanoma is often diagnosed in an early stage when
More informationCLINICALTRIALS.GOV USER GUIDE
CLINICALTRIALS.GOV USER GUIDE If you are a patient, caregiver, or physician looking for investigational therapy options available through either clinical trials or expanded access, you can begin to research
More informationA snapshot of inpatient oncology rehabilitation: Patient profiles and rehab outcomes Rehabilitation Rounds, University of Toronto April 5, 2012
A snapshot of inpatient oncology rehabilitation: Patient profiles and rehab outcomes Rehabilitation Rounds, University of Toronto April 5, 2012 Sara McEwen, PT, PhD Research Scientist, St. John s Rehab
More informationThe Clinical Research E-News
The Clinical Research E-News Volume 3: ISSUE 16: September 28, 2011 Jefferson Kimmel Cancer Network: For urgent clinical trial questions or assistance please page: 877-656-9004 Now Open: C70604, A Randomized,
More informationThe OUTBACK Trial. Specific CRF Completion Guidelines
The OUTBACK Trial A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone (ANZGOG 0902, GOG 0274,
More informationCollecting Real World Evidence: HTA s perspective
Collecting Real World Evidence: HTA s perspective Dr. Kelvin Chan, MD FRCPC MSc (Clin Epi) MSc (Biostats) Clinical Lead, Provincial Drug Reimbursement Programs, CCO Co-Director, Canadian Centre for Applied
More informationPolicy. Medical Policy Manual Approved Revised: Do Not Implement Until 3/2/19. Nivolumab (Intravenous)
Nivolumab (Intravenous) NDC CODE(S) 00003-3772-XX Opdivo 40 MG/4ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3774-XX Opdivo 100 MG/10ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3734-XX Opdivo 240
More informationCancer Prevention and Screening: Working together in NE Aboriginal Communities
Cancer Prevention and Screening: Working together in NE Aboriginal Communities Amanda Hey MD CCFP FCFP Regional Primary Care Lead, Northeast Cancer Centre; October 12, 2012 Source: Cancer Care Ontario
More informationNational, volunteer-based charity focused on finding the cures for Crohn s Crohn's and Colitis Canada
Table 1 Diabetes organisations and groups used for recruitment Support groups and organization About the organization Alberta Children's Hospital & transition clinics Children's hospital in Calgary British
More informationRoche Investor Relations ASCO Planner 2016
Roche Investor Relations ASCO Planner 2016 Friday, June 3 Session Title: Pediatric Oncology I Date: Fri, June 3 Location: S504 Time: 3:00 PM - 6:00 PM Speaker Name: Veronique Minard-Colin 5:12 PM - 5:24
More informationImmune Therapy in Clear Cell Ovarian Cancer (ITICC) Hal Hirte Canadian Cancer Clinical Trials Group
Immune Therapy in Clear Cell Ovarian Cancer (ITICC) Hal Hirte Canadian Cancer Clinical Trials Group Results of Phase II Study of Durvalumab and Tremelimumab in recurrent clear cell ovarian cancer Trial
More informationRespiratory Virus Detections in Canada Respiratory Virus Report, Week 10 - ending March 9, 2019
Respiratory Virus Detections in Canada Respiratory Virus Report, Week 1 - ending March 9, 19 The Respiratory Virus Detection Surveillance System collects data from select laboratories across Canada on
More informationOpen clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A MULTICENTRE, RANDOMIZED PLACEBO-CONTROLLED, DOUBLE-BLIND
More informationDebate: Adjuvant vs. Neoadjuvant Therapy for Urothelial Cancer
Debate: Adjuvant vs. Neoadjuvant Therapy for Urothelial Cancer Kala Sridhar, MD, MSc, FRCPC Medical Oncologist, Princess Margaret Hospital GU Medical Oncology Site Group Head Associate Professor, University
More informationNCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT
NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT The NCIC CTG DSMC reviewed the following trials with respect to safety, trial conduct, including accrual, and
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Malignant melanoma: assessment and management of malignant melanoma 1.1 Short title Malignant Melanoma 2 The remit The Department
More informationThe Clinical Research E-News
Volume 2: ISSUE 5: March 10, 2010 The Clinical Research E-News Coming soon: AZ1071, A Phase II Study Evaluating the Role of Sentinel Lymph Node Surgery and Axillary Lymph Node Dissection Following Preoperative
More informationFully Automated IFA Processor LIS User Manual
Fully Automated IFA Processor LIS User Manual Unless expressly authorized, forwarding and duplication of this document is not permitted. All rights reserved. TABLE OF CONTENTS 1 OVERVIEW... 4 2 LIS SCREEN...
More informationIndex. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.
Surg Oncol Clin N Am 16 (2007) 465 469 Index Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, preoperative for gastric cancer, staging and, 339 B Breast cancer, metabolic
More informationGlobal reporting system for hepatitis (GRSH) data approval manual
Global reporting system for hepatitis (GRSH) data approval manual Contents Acknowledgement... 1 General information... 2 1. Logging in... 2 2. Validating aggregated numbers in the reports application...
More informationNCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT
NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT The NCIC CTG DSMC reviewed the following trials with respect to safety, trial conduct, including
More informationOncology News. primary care providers in the region to ensure that women at higher risk of breast cancer have appropriate access to screening.
North East Oncology News Bringing Care Closer to Home Fall 2013 This special bulletin of North East Oncology News provides updates on the Ontario Breast Screening Program High Risk Screening in the North
More informationThe Clinical Research E-News
The Clinical Research E-News Volume 7: ISSUE 2: February 19, 2015 Jefferson Kimmel Cancer Center Network: For urgent clinical trial questions or assistance please page: 877-656-9004 New Featured Trials
More informationOpen clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1
More informationFirst Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor
September 30, 2014 Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy @ (ipilimumab) Presented at the ESMO 2014 Congress First Phase 3 Results Presented
More informationPolicy. Medical Policy Manual Approved Revised: Do Not Implement until 6/30/2019. Nivolumab
Medical Manual Approved Revised: Do Not Implement until 6/30/2019 Nivolumab NDC CODE(S) 00003-3772-XX Opdivo 40 MG/4ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3774-XX Opdivo 100 MG/10ML SOLN (B-M SQUIBB
More informationOutcomes Report: Accountability Measures and Quality Improvements
Outcomes Report: Accountability Measures and Quality Improvements The FH Memorial Medical Center s Cancer Committee ensures that patients with cancer are treated according to the nationally accepted measures.
More informationPatient Ratings of Overall Care and Likelihood to Recommend Ontario Hospitals. Results of Patient Experience Surveys from April 2011 to March 2012
Patient Ratings of and Likelihood to Recommend Ontario Hospitals Results of Patient Experience Surveys from April 2011 to March 2012 October 2013 Table of Contents About this report... 3 Highlights...
More informationPatient Leader Education Summit. Precision Medicine: Today and Tomorrow March 31, 2017
Patient Leader Education Summit Precision Medicine: Today and Tomorrow March 31, 2017 Precision Medicine: Presentation Outline Agenda What is a Precision Medicine What is its clinical value Overview of
More informationThe SABR Practice Information for oncologists. State-of-the-art care has never been closer. genesiscare.co.uk
The SABR Practice Information for oncologists State-of-the-art care has never been closer genesiscare.co.uk About Stereotactic Ablative Body Radiotherapy SABR is now accepted as the standard of care for
More informationRoche Investor Relations ASCO Planner 2017
Roche Investor Relations ASCO Planner 2017 Saturday, June 3 Session Title: Lung Cancer Non-Small Cell Metastatic Date: Sat, June 3 Time: 8:00 AM 11:30 AM Speaker Name: Ibiayi Dagogo-Jack, MD; Yuichi Takiguchi,
More informationFuture Directions in Immunotherapy
Future Directions in Immunotherapy Naiyer Rizvi, MD Price Chair, Clinical Translational Medicine Director of Thoracic Oncology Director of Immuno-Oncology Columbia University Medical Center New York, New
More informationFacilitating Lu 177 Personalized Dosimetry for Neuroendocrine Tumours CANM 2017
Facilitating Lu 177 Personalized Dosimetry for Neuroendocrine Tumours CANM 2017 CANM ANNUAL SCIENTIFIC MEETING APRIL 20-23, 2017 TORONTO, ONTARIO I do not have a financial interest, arrangement or affiliation
More informationOttawa Network for Borderline Personality Disorder (ON-BPD)
Ottawa Network for Borderline Personality Disorder (ON-BPD) H E L P I N G FA M I L I E S A N D F R I E N D S CO P E W H E N S O M E O N E T H E Y LOV E H A S B P D ON-BPD Presentation to the Royal Mental
More informationAfterCare Program for Childhood Cancer Survivors
AfterCare Program for Childhood Cancer Survivors Princess Margaret Information for childhood cancer survivors and families Read this booklet to learn about: Ontario s Childhood Cancer AfterCare Program
More informationThe Clinical Research E-News
The Clinical Research E-News Volume 2: ISSUE 19: October 13, 2010 Coming soon: RTOG 0929, A Randomized, Phase I/II Study of ABT-888 in Combination with Temozolomide in Recurrent (Temozolomide Resistant)
More informationPERJETA (pertuzumab) FOR TREATMENT OF MALIGNANCIES
PERJETA (pertuzumab) FOR TREATMENT OF MALIGNANCIES Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures,
More informationFive patients needing radiation but no in-country access. Memory Nsingo 15 December 2015
Five patients needing radiation but no in-country access Memory Nsingo 15 December 2015 Radiotherapy project update Remigio Makufa GPH Oncology Physicist MGH ATTACHMENT THERAPIST -January 2015 Clinical
More informationCorporate Medical Policy
Corporate Medical Policy Pertuzumab for Treatment of Malignancies File Name: Origination: Last CAP Review: Next CAP Review: Last Review: pertuzumab_for_treatment_of_malignancies 2/2013 4/2017 4/2018 6/2017
More informationTip Sheet: Investigating an Acute Hepatitis B Event using MAVEN Purpose of Surveillance and Case Investigation:
Tip Sheet: Investigating an Acute Hepatitis B Event using MAVEN Purpose of Surveillance and Case Investigation: To identify clusters of cases or outbreaks, especially those that appear to involve healthcareassociated
More informationThe New CP 3 R Application And Revisions To Standard 4.6 Integration Of The NCDB With The Accreditation Process
The New CP 3 R Application And Revisions To Standard 4.6 Integration Of The NCDB With The Accreditation Process Wednesday, April 29, 2009 at 11 AM Central M. Asa Carter, CTR Manager, Approvals and Standards
More informationCell Reproduction Virtual Lab. Interphase Prophase Metaphase Anaphase Telophase. Name
Name THE CELL CYCLE & CANCER WEBQUEST The human body is made up of trillions of cells that continually grow, reproduce and die. How do our bodies make more cells? And, what does this process have to do
More informationSouth West Regional Cancer Program. Cancer Plan
South West Regional Cancer Program Cancer Plan 2016-2019 1. Cancer System Planning Cancer Care Ontario s role as the government s cancer advisor includes the development and implementation of a provincial
More informationBreastCancerAdvisor by DR. SILVANA MARTINO January 2014
BreastCancerAdvisor by DR. SILVANA MARTINO January 2014 Dear Readers, It is the start of a new year and even as I get a bit older, I still experience great joy at this time. A feeling that there is a new
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Trastuzumab (Herceptin), Trastuzumab-dkst (Ogivri) Reference Number: CP.PHAR.228 Effective Date: 07.01.18 Last Review Date: 05.18 Line of Business: Oregon Health Plan Coding Implications
More informationHOW TO USE THE BENCHMARK CALENDAR SYSTEM
HOW TO USE THE BENCHMARK CALENDAR SYSTEM 1. Go to Website http://doris.clk.co.st-johns.fl.us/benchmarkweb 2. You can use Firefox or Internet Explorer 11 to login to Benchmark. Compatibility mode is no
More informationRecent Therapeutic Advances for Thoracic Malignancies
Recent Therapeutic Advances for Thoracic Malignancies Developed in collaboration Learning Objectives Upon completion, participants should be able to: Interpret new developments in the use of radiation
More informationSt. Joseph s Regional Thoracic Program. Dr. Yaron Shargall (Head, Thoracic Surgery) St. Joseph s Healthcare Hamilton
St. Joseph s Regional Thoracic Program Dr. Yaron Shargall (Head, Thoracic Surgery) St. Joseph s Healthcare Hamilton SJHH REGIONAL THORACIC PROGRAM Collaboration & Integration Thoracic Surgery - Malignant
More informationOne Breast Cancer Annual Report
One 2015 Breast Cancer Annual Report One OVERVIEW The Breast Program at Carolinas HealthCare System s Levine Cancer Institute, offers comprehensive care. Patients with benign and malignant disease of the
More informationPET Steering Committee Meeting Minutes. Wednesday, January 20 th, 2016 Time: 1:30-3:30pm
PET Steering Committee Meeting Minutes Wednesday, January 20 th, 2016 Time: 1:30-3:30pm Committee Members Present: U. Metser (Chair), R. dekemp, M. Freeman, M. Greenberg, D. Hussey, A. Singnurkar, Y. Ung
More informationREFERENCE CODE GDHC476DFR PUBLICAT ION DATE NOVEMBER 2014 CYRAMZA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC476DFR PUBLICAT ION DATE NOVEMBER 2014 CYRAMZA (COLORECTAL CANCER) Executive Summary Table below presents the key metrics of Cyramza for colorectal cancer (CRC) in the eight major pharmaceutical
More information